Citation profile for Yawen Jiang

Yawen Jiang : Citation Profile

H index

i10 index

Citations

RESEARCH PRODUCTION:

Articles

RESEARCH ACTIVITY:

   4 years (2019 - 2023). See details.
   Cites by year: 1
   Journals where Yawen Jiang has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 1 (20 %)

MORE DETAILS IN:

EconPapers Author's homepage

ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pji261
   Updated: 2024-04-18    RAS profile: 2024-01-06
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers

Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Yawen Jiang.

Is cited by:

Cites to:

Keane, Michael (6)

Page, Lionel (5)

Baum, Christopher (5)

Schaffer, Mark (5)

Stillman, Steven (5)

Torgler, Benno (4)

Stock, James (4)

Stavrunova, Olena (3)

Silverman, Dan (3)

Staiger, Doug (3)

Fang, Hanming (3)

Main data

Where Yawen Jiang has published?

Journals with more than one article published	# docs
Health Economics Review	2

Recent works citing Yawen Jiang (2024 and 2023)

Year	Title of citing document
2023	Private health insurance consumption and public health-care provision in OECD countries: Impact of culture, finance, and the pandemic. (2023). Ho, Nhut Quang ; Chao, Chi-Chur ; Trinh, Cong Tam. In: The North American Journal of Economics and Finance. RePEc:eee:ecofin:v:64:y:2023:i:c:s106294082200184x. Full description at Econpapers \|\| Download paper
2023	Life Value Assessment Methods in Emerging Markets: Evidence from China. (2023). Liang, Bolin ; Qiu, Dongyang ; Cao, Aochen ; Tan, Liang. In: Sustainability. RePEc:gam:jsusta:v:15:y:2023:i:10:p:7786-:d:1143060. Full description at Econpapers \|\| Download paper

Works by Yawen Jiang:

Year	Title	Type	Cited
2020	Impact of supplementary private health insurance on hospitalization and physical examination in China In: China Economic Review. [Full Text][Citation analysis]	article	1
2022	Does supplemental private health insurance incentivize household risky financial asset investment? Evidence from the China Household Financial Survey In: International Journal of Health Economics and Management. [Full Text][Citation analysis]	article	0
2023	Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis In: Applied Health Economics and Health Policy. [Full Text][Citation analysis]	article	0
2022	Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life In: The European Journal of Health Economics. [Full Text][Citation analysis]	article	1
2022	Quality of life and cost consequence of delays in endovascular treatment for acute ischemic stroke in China In: Health Economics Review. [Full Text][Citation analysis]	article	0
2019	Risk selection into supplemental private health insurance in China In: Health Economics Review. [Full Text][Citation analysis]	article	2
2019	Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease In: PharmacoEconomics. [Full Text][Citation analysis]	article	0